Mexico, the second largest pharmaceutical market in Latin America with a population of 200 million, faces increasing demand for generic drugs due to factors such as an aging population and the prevalence of non-communicable and communicable diseases. A mix of private, public, and out-of-pocket payment systems drives this demand. Access to medicines is facilitated by three key institutes: The Mexican Institute of Social Security, The Institute of Health and Social Services, and Seguro Popular. Despite approximately 200 pharmaceutical companies serving the market, limited competition among generic drug manufacturers and slow price erosion creates opportunities for foreign pharmaceutical players with diverse portfolios and growth potential. COFEPRIS, Mexico's regulatory agency, oversees the evaluation and approval of all medicinal products for commercialization. While it accepts drugs approved in multiple regulated markets, entry into the Mexican market requires a nuanced approach, typically facilitated by a local agent in a phased manner. The approval process involves four steps for generics and five for new drugs, spanning 90 to 350 days, contingent upon submission quality and process specifics. The dossier comprises three modules, with the ongoing integration of changes to align approval processes with regulated markets and incorporate intellectual property considerations. This research reviews regulatory processes for international pharmaceutical companies, leveraging published literature and expert insights to provide a comprehensive roadmap for expedited approvals. Particularly beneficial for small companies seeking entry into Mexico with their own or licensed generic drugs, this guidance aims to enhance access to highquality, affordable medications for Mexican patients while expanding revenue opportunities for international pharmaceutical firms.

1. Mikulic M. Pharmaceutical market worldwide revenue 2001-2022 [Internet]. Statista. 2023. [cited 2024 Mar 6] Available from: https://www.statista.com/statistics/263102/pharmaceutical-market-worldwide-revenue-since-2001/
2. Coburn J. Mexico’s pharmaceutical industry grows [Internet]. WEDC. 2022 [cited 2024 Mar 6]. Available from: https://wedc.org/export/market-intelligence/posts/mexican-pharmaceutical-industry-grows/
3. PAHO. PAHO Recognizes COFEPRIS as a National Regulatory Authority of Regional Reference - PAHO/WHO | Pan American Health Organization [Internet]. www.paho.org. 2012 [cited 2024 Mar 6]. Available from: https://www.paho.org/en/news/2-7-2012-paho-recognizes-cofepris-national-regulatory-authority-regional-reference
4. Figueroa-Lara A, Gonzalez-Block MA, Alarcon-Irigoyen J. Medical Expenditure for Chronic Diseases in Mexico: The Case of Selected Diagnoses Treated by the Largest Care Providers. PLoS ONE [Internet]. 2016 Jan 8 [cited 2020 Nov 3];11(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706295/
5. Global Data. ShieldSquare Captcha [Internet]. www.globaldata.com. 2022. [cited 2024 Mar 6]. Available from: https://www.globaldata.com/store/report/impact-of-mexico-on-pharmaceutical-industry-theme-analysis/
6. Research SM. Stellar Market Research [Internet]. Stellar Market Research. [cited 2024 Mar 6]. Available from: https://www.stellarmr.com/report/Mexico-Generic-Drugs-Market/1611
7. Labonté R, Gleeson D, McNamara CL. USMCA 2.0: a few improvements but far from a 'healthy' trade treaty. Global Health. 2020 May 6;16(1):43. doi: 10.1186/s12992-020-00565-4. PMID: 32375823; PMCID: PMC7201631.
8. Bonilla-Chacín M, Aguilera N. The Mexican Social Protection System in Health Universal Health Coverage Studies Series (UNICO) UNICO Studies Series No. 1 [Internet]. Available from: https://openknowledge.worldbank.org/server/api/core/bitstreams/90849373-4c5a-5d5f-a657-40eb75ec71aa/content
9. Trejo Gutiérrez F. The Body Called Health Services of the Mexican Institute of Social Security for Welfare Is Created [Internet]. Trejo Gutiérrez Abogados - Somos una Firma Legal basada en un trabajo de excelencia para satisfacer las necesidades de nuestros clientes con conocimiento, compromiso y honestidad. 2022 [cited 2024 Mar 6]. Available from: https://trejogutierrez.com/en/2022/09/04/the-body-called-health-services-of-the-mexican-institute-of-social-security-for-welfare-is-created%ef%bf%bc/
10. Colchero MA, Gómez R, Bautista-Arredondo S. A systematic review of the literature on the impact of the Seguro Popular. Health Research Policy and Systems. 2022 Apr 18;20(1).
11. Chemor Ruiz A, Ratsch AE, Alamilla Martínez GA. Mexico’s seguro popular: Achievements and challenges. Health Systems & Reform. 2018;4(3):194–202.
12. GENERICS/GENERAL. Market penetration of generic drugs in Mexico and Brazil [Internet]. www.gabionline.net. 2023 [cited 2024 Mar 6]. Available from: https://www.gabionline.net/generics/general/market-penetration-of-generic-drugs-in-mexico-and-brazil
13. Pharmexcil, Hyderabad. Pharmaceuticals Export Promotion Council of India Mexico Pharma Market & Regulatory Report [Internet]. 2020. Available from: https://pharmexcil.com/uploads/countryreports/Mexico_Market_Regulatory_report2020.pdf
14. Kannappan S, Darrow JJ, Kesselheim AS, Beall RF. The timing of 30?month stay expirations and generic entry: A cohort study of first generics, 2013–2020. Clinical and Translational Science. 2021 May 31;
15. COFECE. Study the free market and competition in the expired-patent drug markets ... [Internet]. [cited 2023Apr17]. Available from: https://www.cofece.mx/wp-content/uploads/2017/11/Studies-drug-markets_vF-BAJA.pdf
16. ??COFEPRIS - Mexico Ministry of Health [Internet]. Emergo by UL. Available from: https://www.emergobyul.com/resources/cofepris-mexico-ministry-health
17. COFEPRIS. Sitio de Comisión federal para la Protección Contra riesgos sanitarios [Internet]. Ir a la página inicial. [cited 2023Apr17]. Available from: https://www.gob.mx/cofepris
18. Wikipedia. Official Journal of the Federation (Mexico) [Internet]. Wikipedia. Wikimedia Foundation; 2022 [cited 2023Apr17]. Available from: https://en.wikipedia.org/wiki/Official_Journal_of_the_Federation_(Mexico)
19. Olivares. COFEPRIS announces new rules for authorizing Generic Drugs [Internet] in Mexico. Lexology. OLIVARES; 2020 [cited 2023Apr17]. Available from: https://www.lexology.com/library/detail.aspx?g=255014bc-da90-428d-a7bc-00761a2df9ac
20. Israel Ledesma Meléndez and Cirse Paola Cruz Patiño. Mexico - New Federal Law of Protection of Industrial Property [Internet]. Jauregui y Del Valle. 2020 [cited 2024 Mar 6]. Available from: https://jaureguiydelvalle.com/en/mexico-new-federal-law-of-protection-of-industrial-property/
21. COFEPRIS. Consulta de Ensayos clínicos registrados ante COFEPRIS: [Internet]. Cofepris.gob.mx. 2022. Available from: http://siipris03.cofepris.gob.mx/Resoluciones/Consultas/ConWebRegEnsayosClinicos.asp
22. GOBIERNO DE MÉXICO. Sitio en mantenimiento [Internet]. failover.www.gob.mx. [cited 2024 Mar 6]. Available from: https://www.gob.mx/cofepris/documentos/15-paquete-de-liberacion-de-genericos.
23. COFEPRIS Version 1.1 [Internet]. [cited 2024 Jan 22]. Available from: https://www.gob.mx/cms/uploads/attachment/file/811945/Planteamiento_para_WHODrug_1.1_21-03-2023_version_ingles.pdf
24. COFEPRIS. NOM-059-SSA1-2015. [cited 2023Apr17]. Available from: https://mexicanlaws.com/SALUD/NOM-059-SSA1-2015.htm
25. COFEPRIS. NOM-164-SSA1-2015, Good manufacturing practices for drug substances. [Internet]. mexicanlaws.com. [cited 2024 Mar 6]. Available from: https://mexicanlaws.com/SALUD/NOM-164-SSA1-2015.htm.